New Research Suggests Declining Rate of Treatment Discoveries
News Jun 10, 2013
According to a study published in the June issue of the journal Health Affairs, there has been a decline in the extent to which new medical treatments are shown to be significantly more effective than placebos. The findings, says study co-author Mark Olfson, MD, MPH, “suggest that medical breakthroughs that offer large benefits above placebo are becoming less common. As a result, now may be a good time to emphasize research that compares established treatments with one another.”
The study authors randomly selected and analyzed 315 placebo-controlled trials that were reported in four leading medical journals between 1966 and 2010. They found that the average effect size, as measured by the odds ratio (which compares the odds of an outcome resulting from the treatment with the odds of that outcome in absence of the treatment) decreased from a peak of 4.51 (1971–80) to 1.36 (2001–2010).
While placebo-controlled studies are considered to be the gold standard for establishing treatment efficacy, the dwindling effect size over the roughly 40-year period supports the view that renewed attention should be given to research that compares treatments already known to be effective, in terms of outcomes that matter most to patients.
In light of the current study, notes Dr. Olfson, professor of clinical psychiatry at Columbia Psychiatry and a research psychiatrist at the New York State Psychiatric Institute, comparative effectiveness research may be an important direction for future clinical research. “With apparently declining yield from placebo-controlled studies, it makes good sense to place greater emphasis on comparing two or more treatments that are known to be effective, to evaluate whether there are meaningful differences in their tolerability, safety, and costs.”
Tiny Kidneys: Building Better Models to Test DrugsNews
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.READ MORE
Could Alzheimer's Drug Repair Brain Damage After Alcohol Binges?News
A drug used to slow cognitive decline in Alzheimer's disease could offer clues on how drugs might one day be able to reverse brain changes that affect learning and memory in teens and young adults who binge drink.READ MORE
Absolute Antibody and Kerafast Merge Increasing Access to Unique Reagents and Recombinant Antibody TechnologyNews
Absolute Antibody Ltd., and Kerafast Inc., have announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.READ MORE